DIFFUSE LARGE B-CELL LYMPHOMA

This study tests whether adding the drug acalabrutinib to standard chemotherapy can cure more people with untreated diffuse large B-cell lymphoma, an aggressive blood cancer. About 132 adults will take the pill twice daily for up to 14 days, then receive standard chemo and rituxi…

This early-phase study is testing a new treatment for adults with certain types of blood cancer (B-cell lymphomas) that have returned or not responded to standard therapies. The treatment combines a targeted drug (pirtobrutinib) with specially engineered immune cells (LV20.19 CAR…

This study tests whether taking itacitinib pills before CAR-T cell therapy can improve outcomes for people with diffuse large B-cell lymphoma (DLBCL). About 27 adults who are eligible for CAR-T treatment will receive itacitinib daily, followed by standard CAR-T therapy. The main …

This study tests a combination of two drugs, acalabrutinib and rituximab, in patients aged 80+ or 65-79 who are too frail for standard chemotherapy. The goal is to see if this gentler approach is safe and effective for treating diffuse large B-cell lymphoma. About 80 participants…

This early-phase study tests a drug called mosunetuzumab given after a stem cell transplant for people with aggressive B cell lymphomas that have come back or not responded to treatment. Mosunetuzumab is an engineered antibody that helps the body's immune T cells find and kill ca…

This study tests whether adding the oral drug zanubrutinib to standard chemotherapy (R-CHOP) helps people with a specific type of lymphoma (DLBCL) that has certain gene changes. About 21 adults with these mutations will receive the combination. The goal is to see if more patients…

This study tests whether adding a targeted chemotherapy (R-CDOP) plus a spinal injection of methotrexate can prevent brain relapse in people with a high-risk form of diffuse large B-cell lymphoma. About 83 untreated adults will receive the treatment and be followed for two years.…

This early-stage trial tests a new drug called IKS03 in people with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. IKS03 is an antibody-drug conjugate designed to seek out and destroy cancer cells while sparing healthy ones. The study aims to fin…

This early-stage study tests a new drug called AZD0486 in about 227 people with B-cell non-Hodgkin lymphoma, including types like diffuse large B-cell and follicular lymphoma. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals…

This study tests a treatment called axicabtagene ciloleucel, a type of CAR T-cell therapy, in 45 adults with diffuse large B-cell lymphoma that has come back after a long period. The goal is to see if the therapy can make the cancer disappear on scans three months after treatment…

This early-stage study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to better recognize and attack cancer cells. T…

This study tests a new drug called DZD8586 combined with standard treatments for diffuse large B-cell lymphoma (DLBCL), a fast-growing blood cancer. About 150 adults with either untreated or relapsed/refractory DLBCL will receive the combination. Researchers will measure how well…

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people with B-cell lymphoma that has returned or not improved after prior treatment. The goal is to see if this drug mix is safe and can control the c…

This study tests whether adding the experimental drug zilovertamab vedotin to standard chemotherapy (R-CHP) helps people with untreated diffuse large B-cell lymphoma live longer without their cancer growing or spreading, compared to the current standard treatment (R-CHOP). About …

This study tests a new drug called zilovertamab vedotin in children and young adults (up to age 30) whose blood cancers or solid tumors have come back or not responded to treatment. The goal is to see if the drug is safe and can shrink or control the cancer. About 90 participants…

This study tests a new treatment called MB-CART2019.1 for people with a type of blood cancer (diffuse large B-cell lymphoma) that has come back or not responded to treatment. Participants are not able to have a standard stem cell transplant. The study compares the new cell therap…

This study compares two treatment schedules for people with a common type of lymphoma (DLBCL) that is low-risk and not large. All participants first receive 4 cycles of standard chemo (R-CHOP). Those who respond well are then randomly assigned to get either 4 more doses of rituxi…

This study tests whether a stem cell transplant using thiotepa and carmustine can prevent lymphoma from spreading to the brain in high-risk patients. About 36 people with newly diagnosed diffuse large B-cell lymphoma who are at high risk for brain relapse will receive the transpl…

This early-phase study tests whether a patient's own immune cells, modified to target a protein called CD19 on cancer cells, can safely treat several types of non-Hodgkin lymphoma that have come back or not responded to standard treatments. About 36 adults with relapsed or refrac…

This early-stage study tests a new type of CAR-T cell therapy that has been 'armored' with an anti-PD1 feature to help it fight cancer better. It is for adults with diffuse large B-cell lymphoma that has come back or not responded to standard treatments. The main goals are to see…

This early-phase trial tests a new treatment called CLIC-2201 for people with B-cell blood cancers that have come back or not responded to standard therapy. CLIC-2201 is made from a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cell…

This early-phase study tests a two-step approach for people with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma. First, patients receive a radioactive antibody (131-I apamistamab) to prepare the body, followed by CAR T-cell therapy …

This study is for people with B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma whose CAR-T cell therapy didn't quite meet commercial quality standards. Researchers want to see if this slightly off-spec treatment is still safe and effective. About 200 participa…

This early-phase trial tests a new type of CAR-T cell therapy (Meta10-19) for adults with relapsed or refractory diffuse large B-cell lymphoma, a blood cancer that has not responded to standard treatments. The therapy adds a metabolic boost to help the immune cells work better. T…

This early-stage trial tests a new drug, ONM-501, injected directly into tumors, either alone or with another drug (cemiplimab), for people with advanced solid tumors or lymphomas that have not responded to other treatments. The study aims to find the safest dose and check for si…

This study uses a cord blood transplant after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. About 200 participants will receive the transplant to see if it improves survival one year later. The approach aims to replace diseased bone …

This study tests whether adding the immunotherapy drug mosunetuzumab to standard chemotherapy is safe and works better for people with a fast-growing type of lymphoma that has a specific genetic change (c-Myc rearrangement). About 30 adults aged 18-75 who have not been treated be…

This early-phase study tests whether giving specially engineered immune cells (CAR T-cells) along with a vaccine can safely prevent B-cell lymphoma from coming back after a stem cell transplant. About 15 adults with aggressive or recurrent B-cell lymphoma will receive the treatme…

This study looks at how well and how safe the drug glofitamab works for Chinese adults whose diffuse large B-cell lymphoma returned or didn't respond after one prior treatment. About 300 people will take part across multiple hospitals. Researchers will track how long patients liv…

This study tests whether adding the drug selinexor to standard chemotherapy (R-CHOP) can improve outcomes for people with a specific, hard-to-treat type of lymphoma (TP53-mutated DLBCL) who have not had prior treatment. About 42 adults will receive the combination, followed by ma…

This early-phase trial tests a new drug called ZM008, alone and with another drug (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 100 adults with canc…

This early-phase study tests a new type of CAR T cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It is for adults with non-Hodgkin lymphoma that has returned or not responded to prior treatments. The main goals are to check safety and find the best dose…

This study tests a mix of six drugs (ViPOR-P) in people with B-cell lymphoma that came back or didn't respond to prior treatment. The goal is to see if the combination is safe and can shrink tumors. Up to 55 adults will receive up to six 21-day cycles of oral pills and IV infusio…

This study tests whether adding targeted drugs based on a patient's genetic profile to standard chemotherapy (Pola-RCHP) works better than standard chemo alone for people with untreated diffuse large B-cell lymphoma. About 152 adults aged 18-75 with intermediate-to-high risk dise…

This study tests whether the drug acalabrutinib, taken after cell therapy (like stem cell transplant or CAR T-cells), can help prevent relapse in patients with very high-risk large B-cell lymphoma. About 24 adults aged 18-70 will participate. The goal is to see if the drug is tol…

This study tests a combination of three drugs (glofitamab, gemcitabine, and oxaliplatin) in about 100 people with aggressive B-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see if a special steroid plan can reduce a common side effect call…

This study tests whether adding the experimental drug SHR-A1912 to standard chemotherapy (R-GEMOX) works better than chemotherapy alone for people whose diffuse large B-cell lymphoma has come back or not responded to treatment. About 280 adults aged 18–79 will take part. The main…

This early-stage study tests a new type of CAR-T cell therapy for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and attack cancer cells.…

This study tests whether adding a mix of three targeted antibodies (tafasitamab, retifanlimab, and rituximab) before and alongside standard chemotherapy can safely treat people with untreated diffuse large B-cell lymphoma. About 35 adults with this aggressive blood cancer will re…

This study is for people with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to treatment. Researchers want to see if a new way of giving radiation, where part of a tumor gets radiation once a day and another part gets it twice a d…

This study tests whether giving a special type of radiation (ultra-fraction radiotherapy) before CAR-T cell therapy can safely improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma. About 20 adults whose cancer has not responded to at least two pri…

This study tests whether the drug emapalumab can prevent severe cytokine release syndrome (CRS), a common and serious side effect of CAR-T cell therapy. It enrolls 28 adults with certain types of relapsed or refractory large B-cell lymphoma who are receiving standard CAR-T treatm…

This study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for adults with certain B cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The goal is to see if these specially engineere…

This study tests whether giving two additional drugs (mosunetuzumab and/or polatuzumab vedotin) after standard CAR T-cell therapy helps control lymphoma that has returned or not responded to treatment. About 396 adults with certain types of aggressive B-cell lymphoma will be rand…

This study tests an experimental drug, BGB-16673, designed to destroy a protein that helps certain blood cancers grow. It is for people with B-cell cancers like lymphoma or leukemia that have come back or not responded to other treatments. The trial has two parts: first finding a…

This study tests whether giving a targeted radiation drug (131I-Apamistamab) before standard CAR-T cell therapy can safely improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma. About 30 adults will receive the combination to check for side effects…

This study follows about 700 adults with advanced diffuse large B-cell lymphoma or follicular lymphoma who are receiving epcoritamab as part of their routine care. Researchers will track how well the drug works in real-world settings over up to 3 years. The goal is to see how man…

This study is for people with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to standard treatments, especially when they have large tumors. The approach uses tiny beads filled with chemotherapy drugs that are injected directly int…

This study tests two drugs together for people with Richter transformation, a fast-growing lymphoma that can arise from chronic lymphocytic leukemia. The drugs aim to block cancer growth and help the immune system attack the cancer. About 32 adults who have not responded to or ca…

This study tests whether adding the experimental drug zilovertamab vedotin to standard chemotherapy helps people with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. About 290 adults will be randomly assigned to receive either the new combina…

This early-stage trial tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to standard treatments. The study aims to find the safest dose and see if the therapy can control the cancer. Abo…

This early-phase study is testing whether it is safe and possible to collect a patient's own stem cells and give them together with CAR T-cell therapy for blood cancers that have come back or not responded to treatment. About 20 adults aged 18 to 85 with certain types of lymphoma…

This early-stage study tests an experimental drug called ABBV-319 in adults with B-cell cancers (lymphomas and leukemia) that have come back or not responded to treatment. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 154 parti…

This study offers ongoing access to the drug ibrutinib for up to 700 people with certain blood cancers (like chronic lymphocytic leukemia or mantle cell lymphoma) who are already taking it and benefiting. The goal is to track long-term safety and see how well the drug controls th…

This study is for people with certain types of lymphoma (B-cell or Hodgkin) that have come back or not responded well to treatment. Participants first receive a stem cell transplant using their own cells, then if their disease is stable or better, they get up to 8 doses of a targ…

This early-phase study tests an experimental oral drug called LP-168 in about 60 adults with several types of B-cell blood cancers (like lymphoma and leukemia) that have returned or not responded to prior treatments. The main goals are to find the safest dose and understand how t…

This study tests a new drug called TQB2825 combined with standard immunochemotherapy for people with diffuse large B-cell lymphoma (DLBCL), either newly diagnosed or relapsed. The goal is to see if the combination improves tumor shrinkage and controls the disease longer. About 90…

This study looks at how chemotherapy affects thinking and memory in people with diffuse large B-cell lymphoma. Researchers will test cognitive function at the start, after the first chemo cycle, and one year later. They also analyze spinal fluid in some patients to find biologica…

This study is for people newly diagnosed with a type of lymphoma called DLBCL. Researchers want to see if a blood test that tracks tumor DNA can help decide who can safely stop chemotherapy early. About 40 participants will get standard treatment, and those whose blood test shows…

This study looks at whether a natural cell process called trogocytosis can help predict if CAR-T cell therapy will work for people with a type of blood cancer called diffuse large B-cell lymphoma. Researchers will measure trogocytosis levels in blood samples from 85 patients befo…

This study looks at whether a new test on spinal fluid can find signs of lymphoma in the brain earlier than standard methods. It involves 50 people with aggressive B-cell lymphoma who are at high risk for the cancer spreading to the central nervous system. Researchers will track …

This study follows up to 500 people who received CAR-T cell therapy for blood cancers like leukemia, lymphoma, or multiple myeloma. Researchers will track participants for up to 15 years to see if any new cancers develop. The goal is to understand the long-term safety of this tre…

This study is for people with certain types of aggressive lymphoma (DLBCL or high-grade B-cell lymphoma) who have changes in the MYC gene. Researchers want to learn how these genetic changes relate to the immune environment around the tumor and how they affect treatment success. …

This study looks at how the flu and COVID vaccines affect the immune system in people with different types of lymphoma. Researchers will measure antibody levels and immune cells over time, comparing them to people without lymphoma. The goal is to better understand how lymphoma an…

This study compares blood samples from people with primary central nervous system lymphoma (PCNSL), those with a related lymphoma outside the brain, and healthy volunteers. Researchers will look for unique chemical and immune cell patterns that could help tell these conditions ap…

This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. About 30 participants who already take venetoclax this way will have their blood levels measured. T…

This study looks at whether CAR-T cell therapy reduces the protection that vaccines (like measles, mumps, and rubella) provide in people with multiple myeloma and non-Hodgkin lymphoma. Researchers will measure antibody levels before and after CAR-T treatment in 45 adults. The goa…